Two New Drugs Now Available to Treat SPMS

The FDA-approved medications offer additional treatment options for people living with active secondary progressive multiple sclerosis (SPMS).  Until the last few months, the vast majority...

FDA Approves Siponimod (Mayzent ) for Multiple Sclerosis

The US Food and Drug Administration (FDA) has approved siponimod (Mayzent®) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include...

NMSS announces University of California scientist as winner of Barancik Prize for Innovation in...

The National Multiple Sclerosis Society has announced Katerina Akassoglou, Ph.D., a leading researcher at the Gladstone Institute of Neurological Disease and the Department of...

Novartis Announces FDA and EMA Filing Acceptance of Siponimod for Secondary Progressive Multiple Sclerosis...

Novartis announced this week that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company's New Drug...

Phase 2 Trial of Ibudilast Shows Slowing of Brain Shrinkage in Progressive MS

Patients living with primary progressive multiple sclerosis have eagerly been awaiting the results from phase 2 of the ibudilast study. It is the hope...

Mayo Clinic develops neuro test that distinguishes demyelinating diseases from MS

If you are like me and first presented with vision loss, transverse myelitis, neuromyelitis optica, or other inflammatory demyelinating disease that was not distinguishable...

Researchers discover new subtype of multiple sclerosis

Cleveland Clinic researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the individualized nature of the disease.MS has...

New drug target for remyelination in MS is identified by UB researchers

Photo: Myelin (green) production by transplanted human oligodendrocyte progenitors cells (red) is greatly improved following the genetic block of M3R expression. (Credit: Jesslie J....

Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of...

No evidence of disease activity-3 (NEDA-3), defined as absence of clinical relapse, disability progression, and brain magnetic resonance imaging (MRI) activity, has emerged as...

Researchers Discover a New Mechanism of the Gene Variant that is a Risk Factor...

While the DNA sequence remains the same throughout a person's life, the expression of the encoded genes may change with time and contribute to...

Social Media

834FollowersFollow